BSX
Boston Scientific Corp
Boston Scientific Corp historical holders
total: 8
Egerton Capital Boston Scientific Corp transactions over time
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Held since:
- 2025 Q2
- Held for:
- 3 quarters
- Latest activity:
- 2026 Q1
John Armitage has been an institutional investor in Boston Scientific Corp (BSX) since 2025 Q2. According to 2026 Q2 report, John Armitage doesn't hold any shares. The fund/company first acquired BSX in 2025 Q2, initially purchasing about 1.64M shares. Since the initial investment, Egerton Capital has made 3 more transactions in this position.
When did John Armitage exit their BSX position?
John Armitage no longer holds Boston Scientific Corp (BSX). They sold off their entire position in 2026 Q1, closing out an investment that began in 2025 Q2.
When did John Armitage first invest in BSX?
John Armitage first invested in Boston Scientific Corp (BSX) in 2025 Q2 at the reported quarter-end price of $107.41 per share, acquiring 1,640,956 shares in their initial purchase.
What is John Armitage's average cost basis for BSX?
Based on historical transaction data, John Armitage's estimated cost basis for Boston Scientific Corp (BSX) is approximately $100.58 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $100.58
- Weighted AVG sell price:
- $95.35
BSX transactions history by Egerton Capital
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
0
|
$95.35
|
|
-100% (-5,385,084)
|
-5.58%
|
|
2025 Q4
|
5.58%
|
5,385,084
|
$95.35
|
$513,467,759
|
+1.37% (+72,580)
|
+0.08%
|
|
2025 Q3
|
5.47%
|
5,312,504
|
$97.63
|
$518,659,766
|
+223.74% (+3,671,548)
|
+3.78%
|
|
2025 Q2
|
1.81%
|
1,640,956
|
$107.41
|
$176,255,084
|
new
|
+1.81%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.